Literature DB >> 1891288

Recurrent varicella-zoster virus infections in apparently immunocompetent children.

A K Junker1, E Angus, E E Thomas.   

Abstract

Fourteen generally healthy children (5 females, 9 males, ages 18 months to 13 years) who have developed 2 to 5 attacks of chickenpox are described. Herpes zoster also occurred in 2 of 14 children. No case of chickenpox was severe or associated with complications. General studies of immunoglobulins, specific antibodies to immunization agents, complement and lymphocyte subpopulation number and function indicated that 1 of 14 had low serum IgA and 3 of 14 lacked antibody to 1 (n = 2) or 2 (n = 1) immunization agents. Varicella-zoster virus (VZV)-specific immune studies showed that the children developed VZV-antibody titers by enzyme-linked immunosorbent assay of 1:640 to 1:10 240. By immunoblot assay all appeared to develop a normal spectrum of antibodies to individual VZV proteins. All but one developed VZV cellular immune responses with stimulation indices ranging from 3.6 to 174. Sequential follow-up of 8 patients revealed 1 who became seronegative and 2 who lost VZV cell-mediated immune responses. Chickenpox may recur more frequently than is generally recognized. General and VZV-specific immune investigations are unlikely to indicate a reason.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1891288     DOI: 10.1097/00006454-199108000-00004

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  10 in total

Review 1.  Preventing varicella-zoster disease.

Authors:  Sophie Hambleton; Anne A Gershon
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

2.  Commentary: severe varicella/zoster and adenovirus infections in immunocompromised patients.

Authors:  W R Weir
Journal:  Thorax       Date:  1995-11       Impact factor: 9.139

Review 3.  Pathogenesis and current approaches to control of varicella-zoster virus infections.

Authors:  Anne A Gershon; Michael D Gershon
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

Review 4.  Microbiology laboratory and the management of mother-child varicella-zoster virus infection.

Authors:  Massimo De Paschale; Pierangelo Clerici
Journal:  World J Virol       Date:  2016-08-12

Review 5.  Varicella zoster vaccines and their implications for development of HSV vaccines.

Authors:  Anne A Gershon
Journal:  Virology       Date:  2013-01-05       Impact factor: 3.616

6.  Primary vaccine failure after 1 dose of varicella vaccine in healthy children.

Authors:  David E Michalik; Sharon P Steinberg; Philip S Larussa; Kathryn M Edwards; Peter F Wright; Ann M Arvin; Haley A Gans; Anne A Gershon
Journal:  J Infect Dis       Date:  2008-04-01       Impact factor: 5.226

7.  Breakthrough varicella in a cancer patient with persistent varicella antibody after one varicella vaccination.

Authors:  Masaki Yamada; Natalie Kamberos; Charles Grose
Journal:  J Pediatr       Date:  2013-08-06       Impact factor: 4.406

8.  The consistency of shingles and its significance for health monitoring.

Authors:  Douglas M Fleming; Aad Bartelds; Rachel S Chapman; Kenneth W Cross
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 12.434

9.  Periodicity of varicella-zoster virus in the presence of immune boosting and clinical reinfection with varicella.

Authors:  Igor A Korostil; James G Wood; David G Regan
Journal:  Theor Biol Med Model       Date:  2015-04-11       Impact factor: 2.432

10.  Severe varicella-zoster virus pneumonia: a multicenter cohort study.

Authors:  Adrien Mirouse; Philippe Vignon; Prescillia Piron; René Robert; Laurent Papazian; Guillaume Géri; Pascal Blanc; Christophe Guitton; Claude Guérin; Naïke Bigé; Antoine Rabbat; Aurélie Lefebvre; Keyvan Razazi; Muriel Fartoukh; Eric Mariotte; Lila Bouadma; Jean-Damien Ricard; Amélie Seguin; Bertrand Souweine; Anne-Sophie Moreau; Stanislas Faguer; Arnaud Mari; Julien Mayaux; Francis Schneider; Annabelle Stoclin; Pierre Perez; Julien Maizel; Charles Lafon; Frédérique Ganster; Laurent Argaud; Christophe Girault; François Barbier; Lucien Lecuyer; Jérôme Lambert; Emmanuel Canet
Journal:  Crit Care       Date:  2017-06-07       Impact factor: 9.097

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.